Global Health Research Center of Central Asia, Almaty, Kazakhstan; Columbia University School of Social Work, New York City, United States; Global Health Research Center of Central Asia, United States.
Global Health Research Center of Central Asia, Almaty, Kazakhstan; Columbia University School of Social Work, New York City, United States; Global Health Research Center of Central Asia, United States.
Int J Drug Policy. 2018 Apr;54:105-113. doi: 10.1016/j.drugpo.2018.01.004. Epub 2018 Feb 8.
To evaluate the efficacy of a couple-based integrated HIV/HCV and overdose prevention intervention on non-fatal and fatal overdose and overdose prevention behaviors among people who use heroin or other opioids in Almaty, Kazakhstan.
We selected 479 participants who reported lifetime heroin or opioid use from a sample of 600 participants (300 couples) enrolled in a randomized controlled trial (RCT) conducted between May 2009 and February 2013. Participants were randomized to either (1) a 5-session couple-based HIV/HCV and overdose prevention intervention condition or (2) a 5-session Wellness Promotion and overdose prevention comparison condition. We used multilevel mixed-effects model with modified Poisson regression to estimate effects of the intervention as risk ratios (RR) and the corresponding 95% CIs.
About one-fifth (21.9%) of the sample reported that they had experienced an opioid overdose in the past 6 months at baseline. At the 12-month follow-up, both the intervention and comparison conditions reported significant reductions in non-fatal overdose and injection heroin/opioid use and significant increases in drug treatment attendance and naloxone use to prevent death from overdose. However, we found no differences between the study arms on any of these outcomes. There were three intervention condition participants (1.3%), compared to seven comparison condition participants (2.9%) who died from opioid overdose during the 12-month follow up period although this difference was not significant.
There were no significant conditions on any outcomes: both conditions showed promising effects of reducing non-fatal overdose and overdose risks. Integrating overdose prevention into a couple-based HIV/HCV intervention may be an efficient strategy to target the syndemic of opioid overdose, HIV and HCV in Kazakhstan.
评估一项基于伴侣的综合艾滋病毒/丙型肝炎和过量预防干预措施对哈萨克斯坦阿拉木图使用海洛因或其他类阿片药物者的非致命和致命药物过量及过量预防行为的疗效。
我们从一项于 2009 年 5 月至 2013 年 2 月期间进行的随机对照试验(RCT)中招募的 600 名参与者(300 对伴侣)的样本中选择了 479 名报告有终生使用海洛因或阿片类药物的参与者。参与者被随机分配到以下两种干预条件之一:(1)5 节基于伴侣的艾滋病毒/丙型肝炎和过量预防干预条件,或(2)5 节健康促进和过量预防比较条件。我们使用多级混合效应模型和修正泊松回归来估计干预的效果,采用风险比(RR)和相应的 95%置信区间(CI)进行估计。
在基线时,约五分之一(21.9%)的样本报告在过去 6 个月内经历过阿片类药物过量。在 12 个月的随访中,干预组和对照组均报告非致命性药物过量和注射海洛因/阿片类药物使用减少,药物治疗就诊和纳洛酮使用以预防药物过量导致死亡的情况增加。然而,我们在任何这些结果上都没有发现两组之间的差异。在 12 个月的随访期间,有 3 名干预组参与者(1.3%)死于阿片类药物过量,而对照组有 7 名参与者(2.9%),尽管这一差异无统计学意义。
在任何结果上,两组之间都没有显著差异:两组都显示出减少非致命性药物过量和药物过量风险的有前景的效果。将过量预防纳入基于伴侣的艾滋病毒/丙型肝炎干预措施可能是针对哈萨克斯坦阿片类药物过量、艾滋病毒和丙型肝炎综合病症的一种有效策略。